MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/j.1600-0714.2010.00976.x

Медицинская библиотека · Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2011

Experience with anti-TNF-α therapy for orofacial granulomatosis.

Elliott Tim, Campbell Helen, Escudier Michael, Poate Tim, Nunes Carlo, Lomer Miranda, Mentzer Alex, Patel Pritash, Shirlaw Penelope, Brostoff Jonathon, Challacombe Stephen, Sanderson Jeremy

Клиническое исследованиеСтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Orofacial granulomatosis (OFG) can be challenging to treat and experience with anti-TNF-α therapy is limited. We report our experience with infliximab (IFX) and adalimumab (ADA) for OFG in 14 patients, the largest reported series to date.

METHODS

A review of patients receiving induction and maintenance IFX for OFG +/- Crohn's disease (CD) for active oral disease failing other therapies was performed. Clinical response defined by global physician assessment, aided by oral disease activity scores, was assessed at 2 months, 1 and 2 years. ADA was considered for patients failing IFX. Adverse events were recorded. Predictors of need for anti-TNF-α therapy were determined by comparison with OFG patients not requiring anti-TNF-α from our overall OFG database (n = 207).

RESULTS

Fourteen patients (9 men) were treated with IFX [OFG only (n = 7), OFG with CD (n = 7)]. Nine patients received concomitant immunosuppression. Median duration of treatment was 18 months. Shortterm response was achieved in 10/14 (71%) patients. Eight of 14 (57%) and 4/12 (33%) patients remained responsive at 1 and 2 years, respectively. Two patients who failed IFX responded to ADA. Factors predicting need for anti-TNF-α therapy were oral sulcal involvement, intestinal CD and a raised C-reactive protein (CRP). Oral sulcal involvement predicted response at 1 and 2 years. Intestinal CD did not predict response. The only significant adverse event was an IFX infusion reaction.

CONCLUSION

IFX provided good short-term response for most OFG patients; however, a significant proportion lost response long term. Adverse events were uncommon. Patients failing IFX may respond to ADA.

Для цитирования: Elliott Tim, Campbell Helen, Escudier Michael, Poate Tim, Nunes Carlo, Lomer Miranda, Mentzer Alex, Patel Pritash, Shirlaw Penelope, Brostoff Jonathon, Challacombe Stephen, Sanderson Jeremy. Experience with anti-TNF-α therapy for orofacial granulomatosis.. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 2011. DOI: 10.1111/j.1600-0714.2010.00976.x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.